Gene activation by CIC::DUX4 requires CBP and/or p300, as drug inhibition of CBP and p300 reverses the regulatory circuitry of the disease, alters the expression of oncogenic pathways and reduces xenograft tumor burden (Bosnakovski et al., 2021). The gene discussed is DUX4; the disease is neoplasm.